Study Finds Changes in Seronegative RA Diagnoses Over 10 Years

Over a decade, 13% of patients with seronegative rheumatoid arthritis received a new diagnosis, often spondyloarthritis, and over a quarter achieved drug-free remission.

Jan. 29, 2026 at 3:15am

Got story updates? Submit your updates here. ›

A retrospective study of 176 adults with seronegative rheumatoid arthritis (RA) in Minnesota found that by 10 years, 12.8% received a different diagnosis, most commonly spondyloarthritis, and 26.6% achieved drug-free remission. About 20% started a biologic or targeted synthetic disease-modifying antirheumatic drug (DMARD) during the study period.

Why it matters

This study highlights the importance of ongoing investigation to improve accuracy in the initial diagnosis of seronegative inflammatory arthritis, as a significant minority of patients received a new diagnosis over time. It also demonstrates that a substantial proportion of seronegative RA patients can achieve long-term drug-free remission, providing insights into the potential prognosis for this patient population.

The details

Researchers conducted a retrospective, population-based cohort study to assess long-term outcomes in 176 adults with incident seronegative RA (mean age 56.3 years, 68% women) diagnosed between 2005 and 2014 in Minnesota. They evaluated changes in diagnosis confirmed at two or more rheumatology visits, drug-free remission, and initiation of biologics and JAK inhibitors over a median follow-up of 11.8 years.

  • The study period was from 2005 to 2014.
  • The median follow-up duration was 11.8 years.

The players

Bradly A. Kimbrough, MD

The lead author of the study, from the Mayo Clinic College of Medicine and Science in Rochester, Minnesota.

Got photos? Submit your photos here. ›

What they’re saying

“Although a change in diagnosis was relatively uncommon compared to other outcomes assessed, ongoing investigation to improve accuracy in initial diagnosis of seronegative inflammatory arthritis is important, which may include specific areas such as advanced imaging, synovial pathology, novel autoantibodies, and integration of artificial intelligence.”

— Bradly A. Kimbrough, MD, Lead author

What’s next

The study authors suggest that further research is needed to improve the accuracy of initial diagnosis in seronegative inflammatory arthritis, including the use of advanced imaging, synovial pathology, novel autoantibodies, and artificial intelligence.

The takeaway

This study provides valuable insights into the long-term outcomes of patients with seronegative rheumatoid arthritis, highlighting the need for ongoing diagnostic refinement and the potential for a substantial proportion of these patients to achieve drug-free remission over time.